Nutra Pharma Corp. (NPHC)

OTCMKTS · Delayed Price · Currency is USD

0.0002

+0.0001 (100.00%)

At close: Jun 22, 2026

100.00% (1Y)

Market Cap	1.43M +88.5%
Revenue (ttm)	323.13K -24.8%
Net Income	-1.10M
EPS	-0.00
Shares Out	7.16B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	190,688
Open	0.0002
Previous Close	0.0001
Day's Range	0.0002 - 0.0002
52-Week Range	0.000001 - 0.0050
Beta	57.50
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 18, 2026

About Nutra Pharma

Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases in the United States. The company offers Nyloxin/Nyloxin Extra Strength, an over-the-counter (OTC) pain reliever; Pet Pain-Away, a homeopathic, non–narcotic, non–addictive, over–the–counter pain reliever to treat moderate to severe chronic pain in companion animals; Equine Pain-Away, an OTC topical pain reliev... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2000

Employees 6

Stock Exchange OTCMKTS

Ticker Symbol NPHC

Full Company Profile

Financial Performance

In 2025, Nutra Pharma's revenue was $385,307, a decrease of -1.74% compared to the previous year's $392,150. Losses were -$2.05 million, 59.2% more than in 2024.

Financial Statements